Dr. Douglas Gladstone is an Oncologist in Baltimore caring for patients with leukemias and lymphomas; he is recognized nationally as an expert in the care of patients with these disorders. Dr. Gladstone serves as the clinical director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins outpatient blood and marrow program.
Dr. Gladstone received his undergraduate degree in Biology from SUNY Binghamton (Binghamton, NY), earned his M.D. at the New York School of Medicine (NY, NY), completed his Residency at Strong Memorial Hospital of the University of Rochester (Rochester, NY), and Fellowship in Medical Oncology at Johns Hopkins (Baltimore, MD). Dr. Gladstone joined the Johns Hopkins faculty in 2009 after co-directing the blood and marrow transplant program at SUNY Stony Brook (Stony Brook, NY).
His main research interests adopting immunologic and non-chemotherapeutic treatment straggles to treat hematologic malignancies. In 2018, he helped Moextumomab pasudotox obtain FDA approval for refractory Hairy CelL Leukemia, the first FDA approved for HCL in decades. Currently, Dr. Gladstone, is leading a national trial of cord blood derived immunotherapy to treat COVID-19 patients.
Dr. Gladstone has a passion for teaching trainees and has taught at Johns Hopkins, medical students, residents and fellows and received numerous teaching awards and accolades.